131 I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease

Author(s):  
A.J.M. Ortega ◽  
R.G. Vázquez ◽  
J.I.C. Cuenca ◽  
M.A.M. Brocca ◽  
J. Castilla ◽  
...  
Endocrine ◽  
2003 ◽  
Vol 21 (3) ◽  
pp. 227-232 ◽  
Author(s):  
Tien-Hsiang Wang ◽  
Chen-Hsen Lee ◽  
Ling-Ming Tseng ◽  
Ren-Hsieng Liu

2016 ◽  
Vol 35 (1) ◽  
pp. 29-33
Author(s):  
A.J.M. Ortega ◽  
R.G. Vázquez ◽  
J.I.C. Cuenca ◽  
M.A.M. Brocca ◽  
J. Castilla ◽  
...  

Thyroid ◽  
2005 ◽  
Vol 15 (12) ◽  
pp. 1321-1331 ◽  
Author(s):  
Jennifer P. Holst ◽  
Kenneth D. Burman ◽  
Frank Atkins ◽  
Jason G. Umans ◽  
Jacqueline Jonklaas

Thyroid ◽  
2008 ◽  
Vol 18 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Asli Nar Demirer ◽  
Yasemin Kemal ◽  
Alptekin Gursoy ◽  
Mustafa Sahin ◽  
Neslihan Bascil Tutuncu

Author(s):  
Mallika Bhat ◽  
Matty Mozzor ◽  
Savneek Chugh ◽  
Vamsi Buddharaju ◽  
Monica Schwarcz ◽  
...  

Summary We describe detailed administration of thyroidal and extrathyroidal doses of radioiodine to a patient with end-stage renal disease on hemodialysis. A thorough description of area under curve measurements in a patient with compromised renal function has rarely been described in the literature. Few publications have described thyroid cancer management of patients on hemodialysis, and we believe our management will aid in patient treatment in the future. Learning points: Scheduling of hemodialysis is important when administering radioactive iodine. Treatment of thyroid cancer with radioiodine in patients with end-stage renal disease requires multidisciplinary approach coordinating dialysis, nuclear medicine and endocrinologists care. Balancing ideal dosage of I131 and the timing of dialysis to insure maximal thyroidal uptake and minimal extra thyroidal I131 concentration is necessary.


Sign in / Sign up

Export Citation Format

Share Document